1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About

Scipher Medicine Corporation

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2014

Location

Waltham MA US

Primary Industry

Biotechnology

About

Based in Massachusetts, US, Scipher Medicine Corporation (Scipher Medicine) was founded in 2014 by co-founders Dr. Joe Loscalzo and Dr. Albert-Laszlo Barabasi. In 2003, the founders started building the map of human disease biology that explains how proteins expressed from the human genome interact to cause specific diseases. In 2016, researchers of the company began to develop predictive drug response tests. After studying and surveying the healthcare community to identify major therapeutic and financial pressure points, in 2017 Scipher applied its analysis to create a blood test for predicting medication response to anti-TNF therapies. In March 2021, Scipher Medicine Corporation raised USD 82 million in series C funding co-led by new investor aMoon and returning investor Northpond Ventures. Scipher Medicine Corporation develops a suite of drug development platforms that analyze genetic information to determine suitable therapeutics using machine learning and artificial intelligence. The firm's offerings include ScipherIx, a protein-mapping platform for identifying patient population subgroups; ScipherDx, a drug response prediction platform; and ScipherRx, a drug development platform utilizing gene expression data and applying them to ScipherIx. The company plans to extend commercial efforts for its patient molecular signature test, PrismRA®, to ensure that rheumatoid arthritis patients are administered effective personalized therapy from the onset, as well as data partnerships to explore novel treatment targets based on its broad and growing patient clinical-genomic database created from studied patients.
Current Investors
Khosla Ventures, Alumni Ventures Group, Granpool

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Pharmaceutical Research & Development, Scientific Software, Analytics & Performance Software
Website
www.sciphermedicine.com
Verticals
Artificial Intelligence, HealthTech
Company Stage
Series D
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.